Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

General practitioners will be able to prescribe the weight loss injection tirzepatide (Mounjaro) to “prioritised patient cohorts” from 23 June, NHS England has said. New interim commissioning guidance ...

Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

Key Takeaways Hims & Hers is now offering Zepbound and generic liraglutide for weight lossZepbound is priced at ...

In her latest Instagram post, Meghan Trainor opens up about her weight loss journey, crediting the diabetes medication ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

It’s a little disheartening that so many of the questions (and comments) were focused on my body instead of my music, my ...

Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...